RedHill Biopharma (RDHL) Amortization (2016 - 2025)
RedHill Biopharma has reported Amortization over the past 15 years, most recently at $19.2 million for Q4 2025.
- Quarterly Amortization fell 13.51% to $19.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19.2 million through Dec 2025, down 13.51% year-over-year, with the annual reading at $19.2 million for FY2025, 13.51% down from the prior year.
- Amortization was $19.2 million for Q4 2025 at RedHill Biopharma, down from $22.3 million in the prior quarter.
- Over five years, Amortization peaked at $193.5 million in Q3 2022 and troughed at -$2.9 million in Q4 2022.
- The 5-year median for Amortization is $22.2 million (2024), against an average of $51.6 million.
- Year-over-year, Amortization tumbled 121.36% in 2022 and then skyrocketed 780.62% in 2023.
- A 5-year view of Amortization shows it stood at $13.7 million in 2021, then crashed by 121.36% to -$2.9 million in 2022, then skyrocketed by 780.62% to $20.0 million in 2023, then grew by 11.21% to $22.2 million in 2024, then dropped by 13.51% to $19.2 million in 2025.
- Per Business Quant, the three most recent readings for RDHL's Amortization are $19.2 million (Q4 2025), $22.3 million (Q2 2025), and $22.2 million (Q4 2024).